212-681-1575

In Dec. 2015 the U.S. Food and Drug Administration approved Alecensa (alectinib) for the treatment of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in patients who have progressed on or are intolerant to Xalkori (crizotinib). Now, results from a ...
Continue Reading

Want Specific topic updates?

The National Cancer Society reports that 90 percent of all cancer deaths occur when the cancer cells migrate beyond the primary cancer site to distant organs. Stopping tumor growth ...

Read Full Story

Want Specific topic updates?

A mesothelioma doctor checking the lung x-ray

Immunotherapy has been making headlines as one of the most significant breakthroughs in cancer care in decades. The anti-cancer drugs Keytruda and Opdivo  have led the way as immu ...

Read Full Story

Want Specific topic updates?

April 1-5 was the annual meeting of the American Association for Cancer Researchers (AACR) held in Washington, D.C. During the week-long conference, researchers and physicians from ...

Read Full Story

Want Specific topic updates?

In July, MesotheliomaHelp reported on a phase I clinical trial where various cancers, including mesothelioma, were being tested for the safety and tolerability of the drug avelumab ...

Read Full Story

Want Specific topic updates?